Kiniksa Pharmaceuticals International (KNSA) Inventory Average (2021 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Inventory Average for 6 consecutive years, with $72.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Inventory Average rose 105.08% year-over-year to $72.0 million; the trailing twelve-month figure through Jun 2026 stood at $72.0 million (up 105.08% YoY), and the FY2025 full-year result was $40.6 million, up 41.35% from the prior year.
• Inventory Average rose to $72.0 million in Q2 2026 per KNSA's latest filing, from $64.0 million in the prior quarter.
• Across five years, Inventory Average topped out at $72.0 million in Q2 2026 and bottomed at $8.4 million in Q1 2022.
• Historically, Inventory Average has averaged $31.5 million across 5 years, with a median of $27.9 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Inventory Average soared 290.26% in 2022, then retreated 17.07% in 2025.
• Over 5 years, Inventory Average stood at $18.1 million in 2022, then soared by 56.56% to $28.4 million in 2023, then fell by 2.93% to $27.5 million in 2024, then surged by 74.93% to $48.1 million in 2025, then surged by 49.62% to $72.0 million in 2026.
• According to Business Quant data, Inventory Average over the past three periods registered $72.0 million, $64.0 million, and $48.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.